The effect of 6-TG treatment in BRCA2-knockdown prostate cancer cells before and after reconstitution of BRCA2 levels by ectopic expression was compared with treatment with olaparib, a Food and Drug Administration (FDA)-approved PARP inhibitor. Here, BRCA2 is linked to prostate carcinoma.